BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
IMJUDO (tremelimumab) by AstraZeneca is ctla-4-directed antibody interactions [moa]. Approved for ctla-4-directed blocking antibody [epc]. First approved in 2022.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMJUDO (tremelimumab) is a monoclonal antibody that blocks CTLA-4, an immune checkpoint, to enhance T-cell activation and anti-tumor immunity. It is approved for treatment across 25+ solid tumor indications including hepatocellular carcinoma, non-small cell lung cancer, urothelial cancer, pancreatic cancer, and melanoma. The drug works by removing immune suppression, enabling the body's immune system to recognize and attack cancer cells.
$2MPart D
PeakEarly-stage peak lifecycle with modest Medicare uptake ($2M, 65 claims in 2023) suggests significant growth runway and active brand-building opportunities.
Mechanism of Action
CTLA-4-directed Antibody Interactions
Pharmacologic Class:
CTLA-4-directed Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Started May 2026
29 enrolled
Combined Hepatocellular and Cholangiocarcinoma
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Started Apr 2026
200 enrolled
Hepatocellular Carcinoma
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Started Apr 2026
220 enrolled
Advanced Unresectable Hepatocellular Carcinoma
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Started Apr 2026
40 enrolled
Locally Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Started Nov 2025
196 enrolled
Hepatocellular Carcinoma
Worked on IMJUDO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.